PFE Beats Q3 Earnings & Sales Estimates, Raises 2026 Guidance

Pfizer reported Q3 2026 adjusted EPS of $0.87 versus $0.72 consensus and revenue of $16.58 billion versus $16.13 billion; earnings and revenue were relatively flat year over year. The company raised 2026 revenue guidance to $62-$64 billion from $60.5-$62.5 billion and adjusted EPS guidance to $2.95-$3.05 from $2.80-$3.00, citing strong year-to-date performance. Non-COVID revenue rose 7% operationally, while launched and acquired products grew 32%; shares nevertheless declined slightly in premarket trading.

Analysis

The useful signal is portfolio mix, not the headline beat: growth in oncology and specialty products is cushioning the COVID and Prevnar declines, but it has not yet translated into aggregate revenue growth. The 32% growth claim for launched/acquired products is especially vulnerable to a base-size trap; investors should track their absolute contribution and whether growth persists beyond launch uptake. A modest guidance increase supports near-term estimates, while the longer-dated growth ambition remains company guidance, not evidence that patent-related erosion is solved.

For Pfizer (PFE), the next 1–3 months are about delivery against the raised outlook and whether strength in Padcev, Vyndaqel and Nurtec offsets further Primary Care weakness. Over 6–18 months, pivotal readouts could change the pipeline narrative, but the article does not identify trials or probabilities—verify those before paying for the option value. A downside path is renewed Prevnar/COVID weakness or pipeline disappointment forcing estimates lower; upside requires durable growth from newer products, not just continued declines becoming easier to compare against.

Bristol-Myers Squibb (BMY) shares exposure to Eliquis demand through its alliance, but Pfizer’s reported alliance revenue does not establish BMY’s incremental earnings sensitivity. BioNTech (BNTX) faces a less supportive Comirnaty demand signal, though a single quarter does not establish the partnership’s full earnings impact. The contrarian point: the reported beat may look cleaner than underlying demand because COVID declines and Prevnar weakness remain structural risks; conversely, the market may underweight how much a diversified non-COVID portfolio can absorb them. No strong standalone catalyst supports chasing PFE after its year-to-date advance.

Key Decisions for Investors

• PFE: Hold rather than chase; consider a staged long only on post-earnings weakness if the raised 2026 outlook remains intact. Reassess if subsequent guidance or quarterly sales show newer-product growth failing to offset Primary Care declines.
• Track PFE’s absolute sales contributions from Padcev, Vyndaqel, Nurtec and other launched/acquired products—not just their growth rates—and verify the named pivotal readouts, timing and trial endpoints before underwriting 2028 growth.
• BMY: Treat Eliquis as a supportive data point, not a standalone buy signal. Verify BMY’s own alliance economics and earnings commentary before translating Pfizer’s reported revenue growth into BMY estimates.
• BNTX: Avoid a reflexive short based on one Comirnaty quarter. Watch partner disclosures and forward COVID-vaccine demand; sustained weakness in outlook, rather than quarterly volatility alone, would strengthen the bearish case.